首页>投融资
圣诺制药
上市后再融资
圣诺制药（Sirnaomics）是一家核酸干扰新药研发商，公司主要从事进入临床试验阶段的核酸干扰（RNAi）新药的研发与商业化。主要候选产品（STP705）基于其双重靶向性和早期安全性研究结果，目前正在研究用于治疗非黑色素瘤皮肤癌的II期临床研究。
基本信息
-
公司全称圣诺生物医药技术（苏州）有限公司
-
类型核酸干扰新药研发商
-
产业领域药品研发/制造、生物药
-
公司人数51~100人
-
地址苏州工业园区星湖街218号A4楼415单元
-
联系电话0512-62956283
-
邮箱info-sz@sirnaomicschina.com
-
成立时间2008-03-10
投融资
-
2023-05-17IPO后其他轮次800万港元香港科技园
-
2023-05-17上市后再融资800万港元香港科技园
-
2021-12-30IPO3.96亿港元未透露
-
2021-12-30上市4.60亿港元未透露
-
2021-12-20基石投资轮2.23亿港元未透露
-
2021-12-20E~PreIPO2.23亿港元未透露
-
2021-07-01E轮1.05亿美元旋石资本
-
2021-07-01E~PreIPO1.05亿美元旋石资本
-
2020-10-23D轮1.05亿美元仙瞳资本沃森生物隆门资本中源资本旋石资本阳光融汇资本弘陶资本
-
2020-10-23D轮1.05亿美元旋石资本华兴资本中源资本融汇资本弘陶资本仙瞳资本沃森生物隆门资本
-
2019-04-26C+轮2200万美元天际联想投资华润资本瑞友资本旋石资本
-
2018-06-01C轮2500万美元华控基金仙瞳智创广州越秀产业基金前海晟辉
-
2018-06-01C轮2500万美元前海晟辉浩悦资本仙瞳智创华控基金越秀产业基金
-
2016-05-05B轮1000万美元香港旋石资本
-
2015-11-30A轮未透露元禾控股
-
2015-11-30A轮未透露元禾控股
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司，开发工程化单体 IgA 中性粒细胞接合器，以释放中性粒细胞对癌症的肿瘤杀伤能力，以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心（荷兰乌得勒支）进行的开创性工作，并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息